Small molecule · Inhibitor of KAT6 (MYST histone acetyltransferase) (KAT6A) and KAT6B (MORF; MOZ2; MYST4) (KAT6B) · developed by Pfizer
Prifetrastat is an inhibitor of the MYST histone acetyltransferases KAT6A and KAT6B, which acetylate histones and other nonhistone substrates. By blocking this activity it is intended to disrupt gene expression in tumors that overexpress KAT6. It is being studied in renal impairment and in healthy adults.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07933848 | Phase 1 | Renal Impairment | Not yet recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy AdultsRenal Impairment
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →